Good Afternoon,
Hope all is well. Here is my TA on Boston Scientific.
What I’m Seeing
Looking at Boston Scientific on the weekly chart, the dominant trend is still bearish. Price has fallen from roughly $105–$110 to $44, remains below a declining weekly trend/average, and has yet to establish a convincing sequence of higher highs and higher lows.
But the behavior of the decline is changing.
I've marked three significant selling events. Earlier in the decline, heavy volume produced substantial downside movement. More recently, additional selling has produced progressively less downside, while volume itself has begun to contract.
At the same time, my daily momentum has turned positive for the first time since November 2025, and the weekly negative directional component has weakened relative to the broader trend-strength measure.
To me, this potentially represents:
aggressive markdown → diminishing selling pressure → stabilization → potential accumulation.
The bottom isn't confirmed, but I think the $40–$45 region deserves attention.
The Volume Progression Is the Most Interesting Part
The first high-volume event occurred around $73–$75.
That didn't stop the decline. Sellers remained in control and price continued significantly lower.
The next major event occurred around $55–$58, again with increasing participation.
Then another occurred around $45–$48.
But look at the difference in price response.
The earlier selling generated large declines.
The later selling generated less additional downside.
That's exactly the relationship I'm interested in near the end of a prolonged markdown.
I'm essentially seeing:
large selling effort → progressively smaller bearish result.
That can indicate seller exhaustion or absorption.
It doesn't prove institutional accumulation—high volume can represent aggressive two-way trading—but if subsequent price action begins producing higher lows, the absorption thesis becomes much stronger.
The $40–$45 Area Is My Decision Zone
This is the most important area on the chart.
Price has spent several months around the low-to-mid $40s and, despite repeated selling pressure, has so far struggled to establish itself materially below this region.
That's a meaningful change from earlier in the decline.
Previously, support levels were temporary.
Price would stabilize, bounce slightly and then continue lower.
Now I'm starting to see time being spent at the lows.
That's potentially how a bottom begins.
So I wouldn't automatically call $40–$45 a buy zone.
I'd call it my observation / potential accumulation zone.
Daily Momentum Turning Positive Matters
Your annotation that daily momentum has turned positive for the first time since November 2025 is particularly interesting.
During most of this decline, momentum and price were aligned:
price ↓ + momentum ↓ = bearish confirmation.
Now that relationship is beginning to separate.
Price remains near its lows, but momentum is starting to improve.
That means I may be seeing a form of momentum divergence developing underneath the price action.
Again, divergence doesn't guarantee reversal.
But when I combine:
declining selling volume + reduced downside progress + improving momentum
I start becoming much more interested in the possibility that the downtrend is maturing.
The Weekly Signal Is Improving Too
Your weekly directional indicator observation strengthens that argument.
The negative directional component crossing underneath the weekly average directional index suggests, according to the way you're using the indicator, that bearish directional pressure is no longer behaving as strongly as it was earlier in the decline.
That's an important distinction.
It doesn't necessarily mean buyers have taken control.
It means sellers may be losing control.
Those are two different stages.
The transition I'm looking for is:
seller exhaustion → equilibrium → buyer control.
I think BSX may be somewhere between the first two.
The August Rally Was Useful Information
The rally from approximately $43 to $51–$52 was important even though it failed.
It showed that buyers can move price when selling pressure temporarily disappears.
But price couldn't sustain itself above $50 and subsequently returned toward the base.
That tells me the reversal isn't mature yet.
What happens on this retest matters much more than the original rally.
If price now holds approximately $42–$44 and subsequently creates another push toward $50, I may have the beginnings of:
low → rally → higher low → breakout.
That's the structural sequence I'm waiting for.
$50–$52 Is My First Major Confirmation
The immediate resistance area is approximately $49–$52.
That's where the August recovery failed.
So I don't become significantly more bullish simply because BSX moves from $44 to $47.
I want the market to prove it can remove the previous swing high.
Ideally:
$40–$45 base → $50–$52 breakout → controlled pullback → $46–$48 holds → continuation.
That would be the first meaningful change from the persistent lower-high structure.
$55–$60 Would Change the Character of the Chart
Above $52, I think $55–$60 becomes the next important area.
That's where one of your previous high-volume selling events occurred and where price accelerated downward.
If BSX can reclaim that region, I'd start viewing the chart very differently.
Instead of simply having a potential bottom, we'd potentially have:
base → higher low → higher high → trend recovery.
After that, the declining weekly average around the low/mid-$60s becomes the major longer-term test.
So my technical roadmap is approximately:
$40–$45 → $50–$52 → $55–$60 → $63–$67 weekly trend.
I want each level reclaimed before assuming the next.
Fundamentals — This Is Not a Broken Business
This is where BSX becomes particularly interesting.
Boston Scientific's Q2 2026 revenue was $5.44 billion, up 7.5% reported and 7.0% organically. GAAP EPS increased to $0.61 from $0.53, while adjusted EPS increased to $0.86 from $0.75. Cardiovascular organic sales grew 7.8%, while MedSurg grew 5.4%.
So unlike some of the distressed charts we've looked at, I'm not dealing with collapsing revenue.
The company is still growing.
That creates an interesting disconnect:
business growing → earnings growing → stock down roughly 60% from its highs.
That doesn't automatically make the stock cheap—the previous valuation may simply have been too high—but it does make me much more interested in what price is doing around these lows.
There Are Real Reasons for the Selloff
I wouldn't dismiss the bearish case, though.
Management lowered its full-year outlook after Q2. Adjusted EPS guidance fell from $3.34–$3.41 to $3.28–$3.32, while organic sales-growth guidance was reduced to 5–6%.
A major reason has been weaker-than-expected demand for the Watchman heart implant, along with increased competition in the U.S. electrophysiology market. Management indicated some of the Watchman pressure could continue into 2027.
So the market isn't repricing BSX for no reason.
Growth expectations have come down.
The question is whether the stock decline has now gone far beyond the deterioration in the underlying business.
And There's a New Short-Term Risk: The Cyberattack
This is important because it happened after the Q2 report.
On September 8, Boston Scientific said a cybersecurity incident discovered August 25 had disrupted global operations, including manufacturing and order processing.
The company said it is now unlikely to meet its previously issued Q3 and full-year 2026 sales and adjusted-profit guidance because of the disruption. Major manufacturing and distribution operations were recovering, but management couldn't yet quantify the full financial impact.
That's a significant near-term uncertainty.
And it may help explain why price has returned toward the lows even after the August rally.
The next major fundamental catalyst is therefore the October 28 Q3 report, when management expects to provide an updated outlook.
Why the Cyber Event Matters to My Technical Thesis
This is actually where price behavior becomes particularly useful.
BSX has just received another piece of legitimately negative news.
Yet price is still sitting around $44 rather than immediately collapsing through the previous lows.
I'm watching that closely.
If a stock receives increasingly negative headlines but stops making meaningful new lows, that's potentially evidence that the market has already discounted substantial bad news.
I wouldn't call that proof yet.
But if the cyberattack's financial consequences become clearer and BSX still holds the $40–$45 area, the support becomes much more meaningful to me.
The Product Pipeline Still Matters
The longer-term business hasn't stopped innovating either.
Boston Scientific's FARAPULSE pulsed-field ablation franchise remains an important cardiovascular growth platform. In Q2, its AVANT GUARD study met its safety and effectiveness endpoints and showed superiority over anti-arrhythmic drugs for the studied persistent atrial-fibrillation population. The company has also begun the pivotal FARADIGM trial for its FARAFLEX mapping and ablation catheter.
That matters because the long-term bull case isn't simply:
"the stock fell a lot."
It's:
the stock experienced severe multiple compression while the company continues growing and investing in important medical-device franchises.
If growth stabilizes after the current operational disruptions, that could eventually provide fundamental support for the technical bottom.
Why This Setup Interests Me
The technical and fundamental pictures are beginning to line up in an interesting way.
Technically:
heavy selling → lower lows → additional selling → less downside progress → declining volume → improving momentum → potential base.
Fundamentally:
continued revenue growth + EPS growth + strong product franchises
but also:
lower guidance + Watchman weakness + EP competition + cyber disruption.
That tells me this isn't a simple story.
The business remains healthy enough that I don't need to bet on corporate survival.
I mainly need to determine whether expectations have finally been reset low enough for price to stabilize.
My Bullish Scenario
My preferred sequence would be:
$40–$45 holds → selling volume continues declining → daily momentum remains constructive → $50–$52 reclaimed → higher low → $55–$60 breakout.
If that happens, the declining weekly trend around roughly $63–$67 becomes the major test.
A successful reclaim of that weekly trend would be the point where I'd start taking a larger reversal much more seriously.
Beyond there, I'd eventually watch the prior breakdown areas around $70–$75 and then $78–$80.
I don't need to predict a return to $100 today.
I want the market to build the staircase first.
My Bearish Scenario
The bearish scenario is straightforward.
If BSX loses approximately $40–$42, particularly with expanding volume and renewed negative momentum, my accumulation thesis weakens considerably.
I'd be especially cautious if that happened alongside a materially worse-than-expected cyberattack impact or another deterioration in underlying growth expectations.
That combination would tell me:
this isn't absorption yet—the market is still repricing the business.
I'd rather wait for another base than guess where the next low will occur.
My Bias
I'm cautiously constructive around $40–$45, but I don't think the weekly reversal has been confirmed yet.
What gets my attention is the combination of:
Repeated selling events producing progressively less downside
Volume beginning to contract near the lows
Daily momentum turning positive
Weekly bearish directional pressure weakening
Price spending more time around $40–$45 rather than immediately breaking lower
An underlying business that still generated 7% organic growth in Q2
Adjusted EPS that increased from $0.75 to $0.86 year over year
But I also have to respect the cyberattack, weaker Watchman trends and reduced growth expectations.
So for me:
$40–$45 = potential accumulation / decision zone.
$50–$52 = first structural confirmation.
$55–$60 = meaningful trend improvement.
$63–$67 = major weekly reversal test.
The key thing I'm watching now is effort versus result.
If sellers continue attacking the $40–$45 area but price refuses to move materially lower, while momentum continues improving, I'll become increasingly interested.
If buyers then push BSX through $50–$52 with stronger participation, I'll have much better evidence that what currently looks like seller exhaustion is actually beginning to transition into accumulation and a new recovery cycle.
Trade Safely
Enjoy!
Hope all is well. Here is my TA on Boston Scientific.
What I’m Seeing
Looking at Boston Scientific on the weekly chart, the dominant trend is still bearish. Price has fallen from roughly $105–$110 to $44, remains below a declining weekly trend/average, and has yet to establish a convincing sequence of higher highs and higher lows.
But the behavior of the decline is changing.
I've marked three significant selling events. Earlier in the decline, heavy volume produced substantial downside movement. More recently, additional selling has produced progressively less downside, while volume itself has begun to contract.
At the same time, my daily momentum has turned positive for the first time since November 2025, and the weekly negative directional component has weakened relative to the broader trend-strength measure.
To me, this potentially represents:
aggressive markdown → diminishing selling pressure → stabilization → potential accumulation.
The bottom isn't confirmed, but I think the $40–$45 region deserves attention.
The Volume Progression Is the Most Interesting Part
The first high-volume event occurred around $73–$75.
That didn't stop the decline. Sellers remained in control and price continued significantly lower.
The next major event occurred around $55–$58, again with increasing participation.
Then another occurred around $45–$48.
But look at the difference in price response.
The earlier selling generated large declines.
The later selling generated less additional downside.
That's exactly the relationship I'm interested in near the end of a prolonged markdown.
I'm essentially seeing:
large selling effort → progressively smaller bearish result.
That can indicate seller exhaustion or absorption.
It doesn't prove institutional accumulation—high volume can represent aggressive two-way trading—but if subsequent price action begins producing higher lows, the absorption thesis becomes much stronger.
The $40–$45 Area Is My Decision Zone
This is the most important area on the chart.
Price has spent several months around the low-to-mid $40s and, despite repeated selling pressure, has so far struggled to establish itself materially below this region.
That's a meaningful change from earlier in the decline.
Previously, support levels were temporary.
Price would stabilize, bounce slightly and then continue lower.
Now I'm starting to see time being spent at the lows.
That's potentially how a bottom begins.
So I wouldn't automatically call $40–$45 a buy zone.
I'd call it my observation / potential accumulation zone.
Daily Momentum Turning Positive Matters
Your annotation that daily momentum has turned positive for the first time since November 2025 is particularly interesting.
During most of this decline, momentum and price were aligned:
price ↓ + momentum ↓ = bearish confirmation.
Now that relationship is beginning to separate.
Price remains near its lows, but momentum is starting to improve.
That means I may be seeing a form of momentum divergence developing underneath the price action.
Again, divergence doesn't guarantee reversal.
But when I combine:
declining selling volume + reduced downside progress + improving momentum
I start becoming much more interested in the possibility that the downtrend is maturing.
The Weekly Signal Is Improving Too
Your weekly directional indicator observation strengthens that argument.
The negative directional component crossing underneath the weekly average directional index suggests, according to the way you're using the indicator, that bearish directional pressure is no longer behaving as strongly as it was earlier in the decline.
That's an important distinction.
It doesn't necessarily mean buyers have taken control.
It means sellers may be losing control.
Those are two different stages.
The transition I'm looking for is:
seller exhaustion → equilibrium → buyer control.
I think BSX may be somewhere between the first two.
The August Rally Was Useful Information
The rally from approximately $43 to $51–$52 was important even though it failed.
It showed that buyers can move price when selling pressure temporarily disappears.
But price couldn't sustain itself above $50 and subsequently returned toward the base.
That tells me the reversal isn't mature yet.
What happens on this retest matters much more than the original rally.
If price now holds approximately $42–$44 and subsequently creates another push toward $50, I may have the beginnings of:
low → rally → higher low → breakout.
That's the structural sequence I'm waiting for.
$50–$52 Is My First Major Confirmation
The immediate resistance area is approximately $49–$52.
That's where the August recovery failed.
So I don't become significantly more bullish simply because BSX moves from $44 to $47.
I want the market to prove it can remove the previous swing high.
Ideally:
$40–$45 base → $50–$52 breakout → controlled pullback → $46–$48 holds → continuation.
That would be the first meaningful change from the persistent lower-high structure.
$55–$60 Would Change the Character of the Chart
Above $52, I think $55–$60 becomes the next important area.
That's where one of your previous high-volume selling events occurred and where price accelerated downward.
If BSX can reclaim that region, I'd start viewing the chart very differently.
Instead of simply having a potential bottom, we'd potentially have:
base → higher low → higher high → trend recovery.
After that, the declining weekly average around the low/mid-$60s becomes the major longer-term test.
So my technical roadmap is approximately:
$40–$45 → $50–$52 → $55–$60 → $63–$67 weekly trend.
I want each level reclaimed before assuming the next.
Fundamentals — This Is Not a Broken Business
This is where BSX becomes particularly interesting.
Boston Scientific's Q2 2026 revenue was $5.44 billion, up 7.5% reported and 7.0% organically. GAAP EPS increased to $0.61 from $0.53, while adjusted EPS increased to $0.86 from $0.75. Cardiovascular organic sales grew 7.8%, while MedSurg grew 5.4%.
So unlike some of the distressed charts we've looked at, I'm not dealing with collapsing revenue.
The company is still growing.
That creates an interesting disconnect:
business growing → earnings growing → stock down roughly 60% from its highs.
That doesn't automatically make the stock cheap—the previous valuation may simply have been too high—but it does make me much more interested in what price is doing around these lows.
There Are Real Reasons for the Selloff
I wouldn't dismiss the bearish case, though.
Management lowered its full-year outlook after Q2. Adjusted EPS guidance fell from $3.34–$3.41 to $3.28–$3.32, while organic sales-growth guidance was reduced to 5–6%.
A major reason has been weaker-than-expected demand for the Watchman heart implant, along with increased competition in the U.S. electrophysiology market. Management indicated some of the Watchman pressure could continue into 2027.
So the market isn't repricing BSX for no reason.
Growth expectations have come down.
The question is whether the stock decline has now gone far beyond the deterioration in the underlying business.
And There's a New Short-Term Risk: The Cyberattack
This is important because it happened after the Q2 report.
On September 8, Boston Scientific said a cybersecurity incident discovered August 25 had disrupted global operations, including manufacturing and order processing.
The company said it is now unlikely to meet its previously issued Q3 and full-year 2026 sales and adjusted-profit guidance because of the disruption. Major manufacturing and distribution operations were recovering, but management couldn't yet quantify the full financial impact.
That's a significant near-term uncertainty.
And it may help explain why price has returned toward the lows even after the August rally.
The next major fundamental catalyst is therefore the October 28 Q3 report, when management expects to provide an updated outlook.
Why the Cyber Event Matters to My Technical Thesis
This is actually where price behavior becomes particularly useful.
BSX has just received another piece of legitimately negative news.
Yet price is still sitting around $44 rather than immediately collapsing through the previous lows.
I'm watching that closely.
If a stock receives increasingly negative headlines but stops making meaningful new lows, that's potentially evidence that the market has already discounted substantial bad news.
I wouldn't call that proof yet.
But if the cyberattack's financial consequences become clearer and BSX still holds the $40–$45 area, the support becomes much more meaningful to me.
The Product Pipeline Still Matters
The longer-term business hasn't stopped innovating either.
Boston Scientific's FARAPULSE pulsed-field ablation franchise remains an important cardiovascular growth platform. In Q2, its AVANT GUARD study met its safety and effectiveness endpoints and showed superiority over anti-arrhythmic drugs for the studied persistent atrial-fibrillation population. The company has also begun the pivotal FARADIGM trial for its FARAFLEX mapping and ablation catheter.
That matters because the long-term bull case isn't simply:
"the stock fell a lot."
It's:
the stock experienced severe multiple compression while the company continues growing and investing in important medical-device franchises.
If growth stabilizes after the current operational disruptions, that could eventually provide fundamental support for the technical bottom.
Why This Setup Interests Me
The technical and fundamental pictures are beginning to line up in an interesting way.
Technically:
heavy selling → lower lows → additional selling → less downside progress → declining volume → improving momentum → potential base.
Fundamentally:
continued revenue growth + EPS growth + strong product franchises
but also:
lower guidance + Watchman weakness + EP competition + cyber disruption.
That tells me this isn't a simple story.
The business remains healthy enough that I don't need to bet on corporate survival.
I mainly need to determine whether expectations have finally been reset low enough for price to stabilize.
My Bullish Scenario
My preferred sequence would be:
$40–$45 holds → selling volume continues declining → daily momentum remains constructive → $50–$52 reclaimed → higher low → $55–$60 breakout.
If that happens, the declining weekly trend around roughly $63–$67 becomes the major test.
A successful reclaim of that weekly trend would be the point where I'd start taking a larger reversal much more seriously.
Beyond there, I'd eventually watch the prior breakdown areas around $70–$75 and then $78–$80.
I don't need to predict a return to $100 today.
I want the market to build the staircase first.
My Bearish Scenario
The bearish scenario is straightforward.
If BSX loses approximately $40–$42, particularly with expanding volume and renewed negative momentum, my accumulation thesis weakens considerably.
I'd be especially cautious if that happened alongside a materially worse-than-expected cyberattack impact or another deterioration in underlying growth expectations.
That combination would tell me:
this isn't absorption yet—the market is still repricing the business.
I'd rather wait for another base than guess where the next low will occur.
My Bias
I'm cautiously constructive around $40–$45, but I don't think the weekly reversal has been confirmed yet.
What gets my attention is the combination of:
Repeated selling events producing progressively less downside
Volume beginning to contract near the lows
Daily momentum turning positive
Weekly bearish directional pressure weakening
Price spending more time around $40–$45 rather than immediately breaking lower
An underlying business that still generated 7% organic growth in Q2
Adjusted EPS that increased from $0.75 to $0.86 year over year
But I also have to respect the cyberattack, weaker Watchman trends and reduced growth expectations.
So for me:
$40–$45 = potential accumulation / decision zone.
$50–$52 = first structural confirmation.
$55–$60 = meaningful trend improvement.
$63–$67 = major weekly reversal test.
The key thing I'm watching now is effort versus result.
If sellers continue attacking the $40–$45 area but price refuses to move materially lower, while momentum continues improving, I'll become increasingly interested.
If buyers then push BSX through $50–$52 with stronger participation, I'll have much better evidence that what currently looks like seller exhaustion is actually beginning to transition into accumulation and a new recovery cycle.
Trade Safely
Enjoy!
Pernyataan Penyangkalan
Informasi dan publikasi ini tidak dimaksudkan, dan bukan merupakan, saran atau rekomendasi keuangan, investasi, trading, atau jenis lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Ketentuan Penggunaan.
Pernyataan Penyangkalan
Informasi dan publikasi ini tidak dimaksudkan, dan bukan merupakan, saran atau rekomendasi keuangan, investasi, trading, atau jenis lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Ketentuan Penggunaan.